G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid Breastfeeding
American Academy of Pediatrics and other medical experts exclusively recommend to breastfeed the baby for first 6 months. Once you introduce baby to other foods it is recommended to breastfeed for at least first year of babys life. Taking medication while breastfeeding could be tricky as most drugs pass in breast milk. In this article we will evaluate G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid for its safety in breastfeeding.

What is G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid used for?


temporarily relieves: cough due to minor throat and bronchial irritation as may occur with a cold or inhaled irritants your cough to help you sleep helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive.

Purpose: Active ingredients (in each 5 mL = 1 tsp) Purpose Codeine phosphate, USP 10 mg Antitussive Guaifenesin, USP 100 mg Expectorant

Is G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid safe to use while breastfeeding? Can it interfere with growth and development of my kid?

G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid high risk while breastfeeding
G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid consists two active ingredients Codeine phosphate and Guaifenesin and as per our analysis of both we have determined the G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid is unsafe during breastfeeding. We recommend you to check both ingredients below for better understanding of G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid in breastfeeding.

G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid Breastfeeding Analsys


Codeine phosphate while Breastfeeding

Unsafe

CAS Number: 76-57-3

Compound of cough and pain medication. The cytochrome P450-CYP2D6 enzyme catalyzes morphine. It is excreted in breast milk in small amounts, much lower than the dose used for newborns and infants. The plasma levels of infants whose mothers take them are very low, less than usual therapeutic levels and assuming an insignificant relative dose, less than 1.5% (Meny 1993, Naumburg 1988, Findlay 1981), so it was considered safe for use during breastfeeding (Bar-Oz 2003, WHO 2002, AAP 2001, Moretti 2000, Spigset 2000, Mitchell 1999, Meny 1993). However, excessive sedation in the mother or infant may occur if they are rapid metabolizers of codeine to morphine due to an excess of the gene linked to the P450-2D6 enzyme: this occurs in <1% of Chinese, Japanese and Hispanic people; 3% African Americans; 1-10% of Caucasians and 16-29% of North Africans, Ethiopians and Saudis (Halder 2015, Sachs 2013). The genetic diagnosis of this characteristic is not available in usual clinical practice (Madadi, 2011). Codeine through breast milk has been linked to the appearance of neonatal apnea (Naumburg, 1988), drowsiness (Ito, 1993), neurological depression (Madadi, 2008) and, above all, a fatal outcome: a newborn whose mother had this genetic abnormality died at 13 days; the mother was taking 60 mg of codeine twice daily, morphine levels were normal in breast milk, but very high in the child's plasma (Madadi 2007, Koren 2006). Subsequently, the causality of codeine in this case has been called into question (Bateman 2008, Ferner RE 2008, Young 2007). A link has been found between the use of codeine during pregnancy and breastfeeding and the risk of developing neuroblastoma in the infant (Cook, 2004). Because of all this, and with newborns having a limited capacity for opioid elimination (Willmann, 2009) and the existence of more effective alternatives, many authors and institutions advocate completely discouraging its use in infants and breastfeeding mothers (FDA 2017, Al-Adhami 2016, Lazaryan 2015, AEMPS 2015, Sachs 2013, EMA 2013). Other authors advocate cautious use (some even in the case of rapid metabolizers), using the lowest possible effective dose and for no more than 4 days and monitoring for signs of sedation in mother and infant (Royal Berkshire-NHS 2016, Halder 2015, Reece-Stremtan-ABM Protocol#21 2015, Chow 2015, Kelly 2013, UKMi NHS 2013, Rowe 2013, Montgomery-ABM protocol#15 2012, Amir 2011, Madadi 2009, Madadi 2007, FDA 2007). The use of non-steroidal anti-inflammatory drugs (NSAIDs) better controls pain and with fewer side effects than codeine alone or in combination with paracetamol (Palanisamy 2014, Hendrickson 2012, van den Anker 2012, Madadi 2009, Nauta 2009, Willmann 2009), and codeine is not included either in international consensus on the treatment of migraines (Bordini 2016, Worthington 2013). Follow WHO standards for childbirth attendance, reduce cesarean sections and episiotomies, and therefore the need for analgesics in the first few days.

Guaifenesin while Breastfeeding

Low Risk

CAS Number: 93-14-1

It is used as an expectorant, alone or in association with other products. Proofs on its effectiveness are sparse. In some instances, preparations of Guaifenesin may contain alcohol as excipient with a concentration as high as 5%. At latest update, relevant published data on excretion into breast milk were not found. Until more information on this medication is available, other option known to be safer would be recommended, mostly in the post-natal period or in cases of prematurity. If used while breastfeeding, a moderate use with the lowest dose as possible and avoiding those preparations with alcoholic excipient, should be preferred. Because effectiveness is poor and likelihood of side effects does exist, especially in multi-association, the US Agency for Drug Administration (FDA) is currently doing efforts for discontinuation of this and others at-the-counter products, that are formulated for cough relief (Guaifenesin, Dextromethorphan, Phenylephrine, Pseudoephedrine, Brompheniramine, etc.)


G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid Breastfeeding Analsys - 2


Codeine phosphate while Breastfeeding

CAS Number: 76-57-3

Maternal use of codeine during breastfeeding can cause infant drowsiness, central nervous system depression and even death, with pharmacogenetics possibly playing a role.[1][2] Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. Once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of oral codeine to 2-4 days at a low dosage with close infant monitoring, especially in the outpatient setting.[2][3][4][5] If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately.[6] Excessive sedation in the mother often correlates with excess sedation in the breastfed infant. Following these precautions can lower the risk of neonatal sedation.[7] Numerous professional organizations and regulatory agencies recommend that other agents are preferred over codeine or to avoid codeine completely during breastfeeding;[8][9][10][11][12] however, other opioid alternatives have been studied less and may not be safer.[13]

Guaifenesin while Breastfeeding

CAS Number: 93-14-1

Neither the excretion of guaifenesin in milk nor its effect on breastfed infants have been studied. It is unlikely that with usual maternal doses amounts in breastmilk would harm the nursing infant, especially in infants over 2 months of age. It is best to avoid the use of products with a high alcohol content while nursing.



I already used G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid and meanwhile I breastfed my baby should I be concerned?

If you observer abnormal behavior or any other health issue in infant then you should immediately call 911 or contact other contact other emergency service provider in your area otherwise closely monitor the baby and inform your doctor about your G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid usage and time interval of breastfeeding.


My health care provider has asked me to use G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid, what to do?

If your doctor knows that you are breastfeeding mother and still prescribes G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid then there must be good reason for that as G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.


If I am using G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid, will my baby need extra monitoring?

Yes, Extra monitoring is required if mother is using G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid and breastfeeding as it is considered unsafe for baby.


Who can I talk to if I have questions about usage of G Tussin Ac | Codeine Phosphate And Guaifenesin Liquid in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week